Thrivent Financial For Lutherans Veracyte, Inc. Transaction History

Thrivent Financial For Lutherans

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$19.72 - $28.68 $106,685 - $155,158	-5,410 Reduced 4.66%	110,780 $3.05 Million
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $119,492 - $153,869	-5,701 Reduced 4.68%	116,190 $2.96 Million
Q1 2023 May 17, 2023	BUY	$20.58 - $27.89 $1.46 Million - $1.98 Million	70,894 Added 139.02%	121,891 $2.72 Million
Q2 2022 Aug 16, 2022	SELL	$15.45 - $29.52 $152,244 - $290,890	-9,854 Reduced 16.19%	50,997 $1.01 Million
Q1 2022 May 13, 2022	BUY	$21.94 - $42.51 $1.34 Million - $2.59 Million	60,851 New	60,851 $1.68 Million
Q2 2021 Aug 19, 2021	SELL	$32.94 - $56.62 $751,657 - $1.29 Million	-22,819 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$44.47 - $81.38 $1.01 Million - $1.86 Million	22,819 New	22,819 $1.23 Million

311

82M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.14B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.